Detailed information for compound 346857

Basic information

Technical information
  • TDR Targets ID: 346857
  • Name: N-[[4-(4-benzylpiperazin-1-yl)-3-fluorophenyl ]methyl]-5-nitrofuran-2-carboxamide
  • MW: 438.452 | Formula: C23H23FN4O4
  • H donors: 1 H acceptors: 3 LogP: 3.78 Rotable bonds: 8
    Rule of 5 violations (Lipinski): 1
  • SMILES: Fc1cc(CNC(=O)c2ccc(o2)[N+](=O)[O-])ccc1N1CCN(CC1)Cc1ccccc1
  • InChi: 1S/C23H23FN4O4/c24-19-14-18(15-25-23(29)21-8-9-22(32-21)28(30)31)6-7-20(19)27-12-10-26(11-13-27)16-17-4-2-1-3-5-17/h1-9,14H,10-13,15-16H2,(H,25,29)
  • InChiKey: GPXTYYHYFQWXFK-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • N-[[4-(4-benzylpiperazin-1-yl)-3-fluoro-phenyl]methyl]-5-nitro-furan-2-carboxamide
  • N-[[4-(4-benzyl-1-piperazinyl)-3-fluorophenyl]methyl]-5-nitro-2-furancarboxamide
  • N-[[3-fluoro-4-[4-(phenylmethyl)piperazin-1-yl]phenyl]methyl]-5-nitro-furan-2-carboxamide
  • N-[4-(4-benzylpiperazino)-3-fluoro-benzyl]-5-nitro-2-furamide
  • N-[[3-fluoro-4-[4-(phenylmethyl)piperazin-1-yl]phenyl]methyl]-5-nitrofuran-2-carboxamide
  • N-[[3-fluoro-4-[4-(phenylmethyl)-1-piperazinyl]phenyl]methyl]-5-nitro-2-furancarboxamide
  • N-[4-[4-(benzyl)piperazin-1-yl]-3-fluoro-benzyl]-5-nitro-2-furamide
  • 2-Furancarboxamide, N-[[3-fluoro-4-[4-(phenylmethyl)-1-piperazinyl]phenyl]methyl]-5-nitro-
  • AIDS-227796
  • AIDS227796

Targets

Known targets for this compound

No curated genes were found associated with this compound

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Plasmodium vivax glutamine synthetase, putative 0.0151 0.6007 1
Mycobacterium tuberculosis Probable glutamine synthetase GlnA3 (glutamine synthase) (GS-I) 0.0059 0.1633 0.2301
Schistosoma mansoni glutamine synthetase bacteria 0.0059 0.1633 0.1633
Toxoplasma gondii glutamine synthetase, type I, putative 0.0151 0.6007 1
Schistosoma mansoni glutamine synthetase 1 2 (glutamate-amonia ligase) (gs) 0.0235 1 1
Trypanosoma cruzi glutamine synthetase, putative 0.0235 1 1
Mycobacterium ulcerans hypothetical protein 0.0059 0.1633 0.2301
Trichomonas vaginalis glutamine synthetase-bacteria, putative 0.0059 0.1633 1
Brugia malayi glutamine synthetase 0.0084 0.2802 1
Mycobacterium ulcerans glutamine synthetase 0.0151 0.6007 1
Treponema pallidum 1-pyrroline-5-carboxylate reductase (proC) 0.0032 0.0326 0.5
Schistosoma mansoni glutamine synthetase bacteria 0.0059 0.1633 0.1633
Mycobacterium leprae PROBABLE GLUTAMINE SYNTHETASE GLNA2 (GLUTAMINE SYNTHASE) (GS-II) 0.0151 0.6007 1
Trypanosoma brucei glutamine synthetase, putative 0.0235 1 1
Onchocerca volvulus Glutamine synthetase homolog 0.0151 0.6007 0.5
Loa Loa (eye worm) Gln-2 protein 0.0151 0.6007 1
Echinococcus multilocularis glutamine synthetase 0.0235 1 1
Trichomonas vaginalis glutamine synthetase, putative 0.0059 0.1633 1
Trypanosoma cruzi glutamine synthetase, putative 0.0235 1 1
Entamoeba histolytica glutamine synthetase, putative 0.0059 0.1633 0.5
Mycobacterium tuberculosis Probable glutamine synthetase GlnA2 (glutamine synthase) (GS-II) 0.0151 0.6007 1
Entamoeba histolytica glutamine synthetase, putative 0.0059 0.1633 0.5
Leishmania major glutamine synthetase, putative 0.0235 1 1
Wolbachia endosymbiont of Brugia malayi glutamine synthetase 0.0059 0.1633 0.5
Mycobacterium ulcerans glutamine synthetase GlnA1 0.0151 0.6007 1
Plasmodium falciparum glutamine synthetase, putative 0.0151 0.6007 1

Activities

Activity type Activity value Assay description Source Reference
Cmax (ADMET) = 1.64 mg/ml Maximum concentration in female C57BL/6 mice administered with 300 mg/kg, po ChEMBL. 16366608
Cmax (ADMET) = 1.64 mg/ml Maximum concentration in female C57BL/6 mice administered with 300 mg/kg, po ChEMBL. 16366608
F (ADMET) = 21 % Oral bioavailability in female C57BL/6 mice administered with 300 mg/kg, po ChEMBL. 16366608
F (ADMET) = 21 % Oral bioavailability in female C57BL/6 mice administered with 300 mg/kg, po ChEMBL. 16366608
Log10 cfu (functional) = 7.65 Viable number of Mycobacterium tuberculosis colonies in lungs of infected mice after 9 days of administration of 300 mg/kg ChEMBL. 16366608
MIC (functional) = 1.56 ug ml-1 Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as drug level causing 90% growth inhibition after 7 days by microbroth dilution method ChEMBL. 18701298
MIC50 (functional) = 0.014 mg/ml Activity against Mycobacterium tuberculosis in the absence of mouse serum ChEMBL. 16366608
MIC50 (functional) = 0.014 mg/ml Activity against Mycobacterium tuberculosis in the absence of mouse serum ChEMBL. 16366608
MIC50 (functional) = 0.041 mg/ml Activity against Mycobacterium tuberculosis H37Rv in presence of 10% mouse serum ChEMBL. 16366608
MIC50 (functional) = 0.041 mg/ml Activity against Mycobacterium tuberculosis H37Rv in presence of 10% mouse serum ChEMBL. 16366608
MIC50 (functional) = 0.025 ug ml-1 Activity against Mycobacterium tuberculosis H37Rv ChEMBL. 16366608
MIC50 (functional) = 0.025 ug ml-1 Activity against Mycobacterium tuberculosis H37Rv ChEMBL. 16366608
T1/2 (ADMET) 0 Half life in female C57BL/6 mice administered with 300 mg/kg, po ChEMBL. 16366608
Tmax (ADMET) 0 Tmax in female C57BL/6 mice administered with 300 mg/kg, po ChEMBL. 16366608

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.